Marshall Wace LLP Increases Position in Cardlytics, Inc. (NASDAQ:CDLX)

Marshall Wace LLP increased its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 6.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 814,281 shares of the company’s stock after buying an additional 52,081 shares during the period. Marshall Wace LLP owned about 1.67% of Cardlytics worth $6,685,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CDLX. Canton Hathaway LLC lifted its position in shares of Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. XTX Topco Ltd acquired a new position in Cardlytics during the second quarter worth $107,000. Banco Santander S.A. purchased a new stake in Cardlytics during the first quarter worth $199,000. Quest Partners LLC grew its holdings in Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after purchasing an additional 11,061 shares during the last quarter. Finally, Clear Street Markets LLC purchased a new position in shares of Cardlytics in the fourth quarter valued at $199,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Stock Performance

Shares of CDLX opened at $3.20 on Tuesday. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The company’s 50 day simple moving average is $4.68 and its 200 day simple moving average is $8.67. The company has a market capitalization of $156.11 million, a price-to-earnings ratio of -0.72 and a beta of 1.68. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.77 and a current ratio of 1.77.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The business had revenue of $69.64 million for the quarter, compared to analysts’ expectations of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The business’s revenue was down 9.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.57) earnings per share. On average, sell-side analysts predict that Cardlytics, Inc. will post -1.72 EPS for the current year.

Insiders Place Their Bets

In other news, COO Amit Gupta sold 22,699 shares of the company’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total transaction of $196,573.34. Following the completion of the transaction, the chief operating officer now owns 150,569 shares of the company’s stock, valued at approximately $1,303,927.54. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Scott A. Hill bought 40,000 shares of Cardlytics stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Amit Gupta sold 22,699 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total value of $196,573.34. Following the sale, the chief operating officer now directly owns 150,569 shares of the company’s stock, valued at approximately $1,303,927.54. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

CDLX has been the topic of a number of research reports. Craig Hallum cut shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Needham & Company LLC downgraded Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Finally, Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $18.00 to $5.00 in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.